Spironolactone as an Adjunctive Treatment in Neovascular Age-Related Macular Degeneration

Publisher： Karger

E-ISSN： 1663-2699|8|2|314-320

ISSN： 1663-2699

Source： Case Reports in Ophthalmology, Vol.8, Iss.2, 2017-05, pp. : 314-320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 227, Iss. 1, 2012-04 ,pp. : 11-20

Karger

Access to resources Recommend Favorite

Treatment for Submacular Hemorrhage Associated with Neovascular Age-Related Macular Degeneration

By Shultz Ryan W.   Bakri Sophie J.  

Seminars in Ophthalmology, Vol. 26, Iss. 6, 2011-11 ,pp. : 361-371

Informa Healthcare

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

By  

Ophthalmologica, Vol. 234, Iss. 1, 2015-06 ,pp. : 40-54

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite